Christopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide (Xtandi) as a treatment for patients with metastatic hormone-sensitive prostate cancer.

свернуть